lovebta, I agree 100% with your analysis of the treatment of Relenza by the FDA. My point was by so briefly mentioning Relenza in an article criticizing the FDA for being in the pocket of big pharmas, the author implies Elashoff heroically tried to do the right thing, but was ultimately defeated. Relenza is an example of the FDA's common sense ultimately triumphing over an idjt with an agenda - so why is it even mentioned in this article?
Cheers,
John
BTA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
